Home

MARK G FOLETTA

CIK 1236389 · EVP & Chief Financial Officer · last filed 2026-08-04

MARK G FOLETTA is an EVP & Chief Financial Officer who has filed 130 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing shows the insider sold $330.6K of DXCM on Aug 4, 2026. Across all open-market trades the lifetime net is −$8.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$6.49M

Companies

10

Total Filings

130

Lifetime Open-Market Net

-$8.49M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DXCM Director 57,183 $89.53 $5.12M -$5.96M 39 2026-08-04
AMN Director 41,515 $33.11 $1.37M -$1.20M 21 2026-06-17
ENTA Director — $13.52 — $0 7 2026-03-13
Forte Biosciences, Inc. (TOCA) Delisted EVP & Chief Financial Officer 1,003 — — $71.5K 7 2019-10-04
Regulus Therapeutics Inc. (RGLS) Delisted Director 683 $8.16 $5.6K $76.4K 7 2017-12-06
AMN HEALTHCARE SERVICES INC (AHS) Delisted Director 5,532 — — $0 4 2016-04-22
BIOCEPT INC (BIOC) Delisted Interim CFO — $0.43 — $0 1 2015-09-02
AMBIT BIOSCIENCES CORP (AMBI) Delisted Director — $0.54 — $0 2 2014-11-12
AMYLIN PHARMACEUTICALS INC (AMLN) Delisted SVP, Chief Financial Officer 81,344 — — -$1.48M 25 2012-07-26
ANADYS PHARMACEUTICALS INC (ANDS) Delisted Director — — — $0 6 2011-05-27

Recent Filings

130 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-04 DXCM Sell (S) −4,000 -$330.6K EDGAR
2026-08-03 DXCM Notice (144) −2,000 -$170.6K EDGAR
2026-07-31 DXCM Notice (144) −2,000 -$160.0K EDGAR
2026-06-17 AMN Sell (S) −3,681 -$114.4K EDGAR
2026-06-17 DXCM Sell (S) −4,000 -$296.5K EDGAR
2026-06-15 DXCM Notice (144) −4,000 -$302.8K EDGAR
2026-06-15 AMN Notice (144) −3,681 -$114.1K EDGAR
2026-06-01 DXCM Grant (A) +6,331 $0 EDGAR
2026-05-11 DXCM Gift (G) — $0 EDGAR
2026-05-04 AMN Mixed +8,325 $0 EDGAR
Showing 1–10 of 130
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.